The oncologist · 2026
CANLead: Canada as a Phase 1 Clinical Trial Leader - Opportunities, Initiatives, and Collaborative Innovation to Elevate National Competitiveness.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Adile Ashley A, Sran Gagan, Bedard Philippe L, Carlsson Lindsay, Doi Jeffrey, Drummond-Ivars Nancy, Hakgor Sevan, Henderson Amy, Hilton John F, Josephy Philip David, Kremidas Jim, Limoges Jacqueline, Renouf Daniel J, Ross Fiona, Salawu Abdulazeez, Saleh Ramy, Siu Lillian L, Voccia Isabelle, Lewis Hanusya G, Paquette Miney, Razak Albiruni R Abdul, Spreafico Anna
Аннотация
BACKGROUND: Phase 1 oncology clinical trials have become increasingly complex, resource-intensive, but essential to modernize drug development. Despite strong academic infrastructure, Canada remains underrepresented in early-phase cancer trials relative to international peers.
METHODS: To advance this vision, this perspective summarizes barriers and opportunities impacting the conduct of phase 1 oncology clinical trials in Canada, based on discussions from sponsor, patient advocate, ethics, and clinical research site representatives across national major phase 1 units at the inaugural "Practical Workshop of Conducting Phase 1 Trials in Canada."
RESULTS: Current challenges include overly restrictive and complex trial design that increases participant burden, study activation delays, operational inefficiencies, and limited access to investigational therapies following disease progression. However, Canada's integrated academic cancer centers, publicly funded healthcare system, and ongoing advances in harmonization strategies present opportunities to strengthen national competitiveness in global site selection.
CONCLUSION: Participant-centric strategies, earlier collaboration amongst stakeholders, and targeted operational improvements at local, provincial, and national levels are crucial to elevate Canada as a global leader (CANLead) in phase 1 oncology clinical research. Together, the approaches position Canada to advance its competitiveness and take a more prominent role on the international stage, while also providing a practical framework for developing and optimizing phase 1 units globally.
METHODS: To advance this vision, this perspective summarizes barriers and opportunities impacting the conduct of phase 1 oncology clinical trials in Canada, based on discussions from sponsor, patient advocate, ethics, and clinical research site representatives across national major phase 1 units at the inaugural "Practical Workshop of Conducting Phase 1 Trials in Canada."
RESULTS: Current challenges include overly restrictive and complex trial design that increases participant burden, study activation delays, operational inefficiencies, and limited access to investigational therapies following disease progression. However, Canada's integrated academic cancer centers, publicly funded healthcare system, and ongoing advances in harmonization strategies present opportunities to strengthen national competitiveness in global site selection.
CONCLUSION: Participant-centric strategies, earlier collaboration amongst stakeholders, and targeted operational improvements at local, provincial, and national levels are crucial to elevate Canada as a global leader (CANLead) in phase 1 oncology clinical research. Together, the approaches position Canada to advance its competitiveness and take a more prominent role on the international stage, while also providing a practical framework for developing and optimizing phase 1 units globally.